Oncology Medical News about S-1 monotherapy;advanced biliary cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

S-1 monotherapy in patients with advanced biliary tract cancer
Oncology (Karger), 06/30/09

Sasaki T et al. - In a trial to evaluate the efficacy and safety of single-agent S-1 in pts with advanced biliary tract cancer, it was reported that S-1 monotherapy is a feasible and moderately efficacious treatment for advanced biliary tract cancer, as a first- or second-line chemotherapy regimen.

Methods

S-1 was administered orally at a dose of 80 mg/m2 for 28 days, followed by 14 days of rest (1 cycle).
Treatment was repeated until disease progression, unacceptable toxicity, or pt refusal.

Results

45 pts were enrolled; among these, 29 pts received S-1 as first-line chemotherapy and 16 pts received S-1 as second-line chemotherapy.
Response rates for first- and second-line chemotherapy were 17.2 and 18.8%, respectively.
Median times to progression for first- and second-line chemotherapy groups were 4.2 and 5.5 mos, respectively.
Median overall survival and 1-yr survival rate for each group were 8.7 and 8.0 mos and 42.2 and 38.2%, respectively.
Only the first-line chemotherapy group experienced grade 3/4 toxicities, including leukopenia (6.9%), neutropenia (10.3%), anemia (6.9%), thrombocytopenia (10.3%) and total bilirubin elevation (3.4%).

<< Previous
Cancer mortality in patients with schizophrenia

Next >>
Surgical specialty, surgical unit volume, and mortality after...